MicroRNA-298 represses hepatocellular carcinoma progression by inhibiting CTNND1-mediated Wnt/ β-catenin signaling.

In conclusion, our findings provide the first evidence that miR-298 suppresses HCC progression at least partially by targeting CTNND1-mediated Wnt/β-catenin signaling. MiR-298 may be a target for new therapies in HCC patients. PMID: 29990836 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29990836?dopt=Abstract

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 2, 2018 Category: Drugs & Pharmacology Authors: Cao N, Mu L, Yang W, Liu L, Liang L, Zhang H Tags: Biomed Pharmacother Source Type: research